Nilatinib Maleate Tablets Combined With Capecitabine in the Treatment of HER2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastases

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2024

Primary Completion Date

September 30, 2026

Study Completion Date

July 30, 2027

Conditions

Her2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastasis

Interventions

DRUG

Neratinib maleate in combination with capecitabine

Neratinib maleate tablets，Tablets, 40mg/ tablet, 180 tablets/bottle, orally, 240mg once daily, sealed, stored not above 25℃

All Listed Sponsors

lead

Convalife (Shanghai) Co., Ltd.

INDUSTRY